Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Esophageal Neoplasms × eprenetapopt × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 2 Ovarian Neoplasms 2 Myeloproliferative Disorders 2 Myelodysplastic Syndromes 2 Lymphoma, Mantle-Cell 2 Leukemia, Myelomonocytic, Chronic 2 Leukemia, Myeloid, Acute 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Skin Neoplasms 1 Prostatic Neoplasms 1 Neoplasm Metastasis 1 Myeloid Malignancy 1 Melanoma 1 MDS 1 Lymphoma, Non-Hodgkin 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hematologic Neoplasms 1 Esophageal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 161 Fluorouracil 134 Paclitaxel 127 Radiotherapy 125 Oxaliplatin 87 Docetaxel 71 Carboplatin 71 Irinotecan 60 pembrolizumab 58 Capecitabine 57 Leucovorin 56 Radiation 48 Esophagectomy 44 Surgical Procedures, Operative 41 Drug Therapy 38 Neoadjuvant Therapy 28 Cetuximab 25 Nivolumab 24 Bevacizumab 21 camrelizumab 20 Trastuzumab 20 S 1 (combination) 19 Chemoradiotherapy 19 Magnetic Resonance Spectroscopy 18 Epirubicin 16 Albumin-Bound Paclitaxel 16 Blood Specimen Collection 15 tislelizumab 14 Taxes 14 Radiotherapy, Intensity-Modulated 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02999893 2021-12-13

APROC

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Terminated

Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡